Hormonal
A 14-day continuous adaptive infusion of the GLP-1/GCGR co-agonist G3215 produces significant weight loss (mean -2.39 kg) and reduced food intake in adults with overweight or obesity, with adverse effects mitigated by real-time dose adjustment.
This study shows that a 14-day continuous infusion of a specific hormone drug (G3215) can lead to about 2.4 kg of weight loss in adults with overweight or obesity. The drug works by reducing food intake and increasing energy expenditure. Side effects like nausea were common but manageable by adjusting the infusion rate. This approach might offer faster weight loss with better tolerability than current weekly injection options, though it requires wearing a pump for two weeks.
A least-squares mean body weight loss of 2.39 kg was achieved with a 14-day infusion of G3215, compared with 0.84 kg with placebo infusion (p < .05). A reduction in food consumption was also observed in participants receiving G3215... The most common adverse events were nausea or vomiting, which were mild in most cases and mitigated by real-time adjustment of drug infusion.
Why this rating
Phase 1 randomized, double-blind, placebo-controlled trial with a small sample size (N=23 completing) and short duration (14 days).
Source
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist <scp>G3215</scp> , in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
David C. D. Hope et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15448
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →